UBS Group’s Sucampo Pharmaceuticals SCMP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-263,403
| Closed | -$4.73M | – | 8517 |
|
|
2017
Q4 | $4.73M | Buy |
263,403
+224,460
| +576% | +$2.76M | ﹤0.01% | 2405 |
|
|
2017
Q3 | $460K | Buy |
38,943
+12,619
| +48% | +$142K | ﹤0.01% | 4274 |
|
|
2017
Q2 | $276K | Sell |
26,324
-4,445
| -14% | -$45.3K | ﹤0.01% | 4540 |
|
|
2017
Q1 | $339K | Sell |
30,769
-21,847
| -42% | -$254K | ﹤0.01% | 4303 |
|
|
2016
Q4 | $713K | Buy |
52,616
+22,749
| +76% | +$317K | ﹤0.01% | 3851 |
|
|
2016
Q3 | $368K | Buy |
29,867
+25,900
| +653% | +$305K | ﹤0.01% | 4127 |
|
|
2016
Q2 | $44K | Buy |
3,967
+2,351
| +145% | +$26.3K | ﹤0.01% | 5620 |
|
|
2016
Q1 | $18K | Sell |
1,616
-1,294
| -44% | -$16.4K | ﹤0.01% | 6303 |
|
|
2015
Q4 | $50K | Sell |
2,910
-10,756
| -79% | -$193K | ﹤0.01% | 5825 |
|
|
2015
Q3 | $271K | Buy |
13,666
+12,750
| +1,392% | +$292K | ﹤0.01% | 4396 |
|
|
2015
Q2 | $15K | Hold |
916
| – | – | ﹤0.01% | 7148 |
|
|
2015
Q1 | $14K | Buy |
916
+280
| +44% | +$4.34K | ﹤0.01% | 7387 |
|
|
2014
Q4 | $9K | Sell |
636
-3,235
| -84% | -$34.2K | ﹤0.01% | 8524 |
|
|
2014
Q3 | $26K | Buy |
3,871
+2,777
| +254% | +$18.4K | ﹤0.01% | 7678 |
|
|
2014
Q2 | $8K | Buy |
+1,094
| New | +$7.74K | ﹤0.01% | 9148 |
|
Other funds holding SCMP
UBS Group's SCMP Position: Q1 2018 in Review
UBS Group sold out of Sucampo Pharmaceuticals (SCMP) in Q1 2018, closing a stake of 263,403 shares — an estimated $4.73M sold.
UBS Group first reported a position in SCMP in Q2 2014 and held it in 15 quarters. The position peaked at $4.73M in Q4 2017. 2 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.
- UBS Group reported no remaining Sucampo Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
- UBS Group sold 263,403 Sucampo Pharmaceuticals shares in Q1 2018, an estimated $4.73M.
- UBS Group first reported a position in Sucampo Pharmaceuticals in Q2 2014 and held it in 15 quarters.
- UBS Group's Sucampo Pharmaceuticals position peaked at $4.73M in Q4 2017.
- 2 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals as of Q1 2018.
Based on UBS Group's 13F filing for Q1 2018, filed 15 May 2018.